Bayer and Fujifilm could exit the oncology therapy developer through an initial public offering with a $100m placeholder target.
Century Therapeutics, a US-based cancer treatment developer backed by pharmaceutical and chemical group Bayer, has filed to raise up to $100m in an initial public offering on the Nasdaq Global Select Market.
Founded in 2018 and incubated by venture capital firm Versant Ventures, Century has built an allogeneic cell therapy platform to support the development of cancer immunotherapies. Its lead drug candidate, CNTY-101, is being developed to treat lymphoma, a type of cancer that develops in the immune system.
The…
